Why listen?

Global immuno-oncology pioneer Dr. Steven O’Day and his guests aim to keep you ahead of the curve on the prospects of immunotherapy. Their shared goal is to lengthen the survival curve for patients with cancer and their shared conviction is that next-generation immunotherapies are uniquely poised to make such progress happen.

The Immuno-Oncology Curve is produced by Agenus, a clinical-stage biopharmaceutical company that discovers and develops immunotherapies for cancer. Dr. O’Day is the company’s Chief Medical Officer. He joined Agenus in 2021, after a long career as a medical oncologist—and leader of more than 200 clinical trials— focused especially on the development of immunotherapies.

Subscribe at no charge to get full access to the podcast and its archives.

Stay ahead of The Curve.

Please follow The Immuno-Oncology Curve … a podcast but more importantly a path, we believe, to much better outcomes against cancer.

When you subscribe, you will never miss an update—with every new post sent directly to your email inbox.

To learn more about the tech platform that powers this publication, visit Substack.com.

Subscribe to The Immuno-Oncology Curve with Dr. Steven O'Day

A podcast on next-generation immunotherapy developments against cancer.

People

Dr. O’Day is the Chief Medical Officer of Agenus and a global leader in immuno-oncology. As a clinician, he pioneered CTLA-4 inhibition and its treatment breakthroughs. Steven joined Agenus to bring next-generation immunotherapies to patients.